Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.5562
+0.0017 (0.31%)
Feb 24, 2026, 10:31 AM EST - Market open
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 3.35M |
| 60 Degrees Pharmaceuticals | 1.36M |
| HCW Biologics | 422.03K |
| PMGC Holdings | 285.95K |
| Silo Pharma | 72.10K |
GLMD News
- 24 days ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 2 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 2 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 3 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire
- 3 months ago - Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 3 months ago - Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - PRNewsWire
- 3 months ago - Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PRNewsWire
- 6 months ago - Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire